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#3539 NARROW BAND IMAGING WITH HIGH
RESOLUTION BRONCHOVIDEOSCOPE: A NEW
APPROACH TO VISUALISE ANGIOGENESIS IN
SQUAMOUS CELL CARCINOMA OF THE LUNG
Shibuya K, Nakajima T, Yasufuku K, Iyoda A, Suzuki M,
Sekine Y, Iizasa T, Hiroshima K.
Department of Thoracic Surgery and Pathology, Chiba,
Japan.
Eur Respir J 2006, 28 Suppl 50: 601S.
High-resolution video bronchoscopy with narrow band
imaging (HRVB-NBI) is a new endoscopic technique gradually
entering the arena of clinical research. The high resolution, in
combination with the NBI filter for the wavelengths of blue,
green, and red, allows in vivo imaging of angiogenesis.
In this study, the authors examined the micro-vessel
networks of 79 patients with abnormal sputum cytology or
lung cancer. Using this technique, they reported a mean
vessel diameter of 63.7 m for carcinoma in situ, 136.5 m
for early invasive lesions, and 259.4 m for overt squamous
cell carcinoma, respectively (p  0.029).
Editorial comment: This technique is promising to evaluate
the multi-step process of angiogenesis as a part of carcinogenesis
of the bronchus. This is of interest, as it opens possibilities for
endoscopic follow-up of dysplastic lesions in (ex-)smokers, and
perhaps early response evaluation of anti-angiogenic treatments
in patients with established lung cancer.
#3541 EBUS-TBNA FOR MEDIASTINAL
RESTAGING
Krasnik M,* Ernst A,† Eberhardt R,‡ Yasufuku K,§ Herth F.‡
*Department of Cardiothoracic Surgery, Gentofte University
Hospital, Copenhagen, Denmark; †Interventional Pulmonol-
ogy, Beth Israel Deaconess Medical Center, Harvard Medical
School, Boston, Massachusetts, USA; ‡Department of Pneu-
mology and Critical Care Medicine, Thoraxklinik, Heidel-
berg, Germany; and §Department of Thoracic Surgery, Chiba
University, Graduate School of Medicine, Chiba, Japan.
Eur Respir J 2006, 28 Suppl 50: 601S.
The achievement of tumor clearance of mediastinal
lymph nodes (LNs) is an important prognostic element in
patients with stage IIIA-N2 non-small cell lung cancer treated
with induction therapy followed by surgery.
In this abstract, the authors reported their experience
with real-time endobronchial ultrasound-guided transbron-
chial needle aspiration (rt-EBUS-TBNA) to assess mediasti-
nal LNs in patients with IIIA-N2 NSCLC after induction
chemotherapy. A total of 143 LN stations were punctured in
83 patients with either partial response (n  44) or stable
disease (n  39) on CT (computed) scan. In 129 instances,
lymphocytes were seen in the smears. There was no verifi-
cation of positive results, and specificity and positive predic-
tive value were assumed to be 100%. For patients with
negative findings, ensuing thoracotomy was the gold standard
for comparison. Sensitivity of the technique was 70%, and
negative predictive value was not reported.
Editorial comment: Adequate assessment of response to
therapy in both the primary tumor and the mediastinal LNs, is
very important in this setting. The value of the standard tool,
CT scan, is limited, whereas FDG-PET scores better, espe-
cially for primary tumor response (Vansteenkiste J et al,
Lancet Oncol 2004, 5: 531–540). To reassess mediastinal
LNs, re-mediastinoscopy has been used in a few retrospective
series, but a recent prospective Leuven Lung Cancer Group
study with strict methodological design revealed disappoint-
ing results of re-mediastinoscopy in IIIA-N2 NSCLC patients
who already had a thorough initial mediastinoscopy (De Leyn
P et al, J Clin Oncol 2006, 24: 3333–3339). As reported by
Krasnik et al., rt-EBUS-TBNA is a very attractive alternative
for these patients that now needs further validation in pro-
spective comparator studies investigating negative predictive
values and impact on clinical management.
#4388 CAN WE STILL JUSTIFY
PNEUMONECTOMY FOLLOWING
INDUCTION CHEMOTHERAPY?
Mansour Z, Ducrocq X, Vasilesu M, Wihlm JM, Quoix E,
Massard G.
Department of Thoracic Surgery and Pneumology, Stras-
bourg, France.
Eur Respir J 2006, 28 Suppl 50: 763S.
Morbidity and mortality associated with pneumonec-
tomy after induction therapy have been reported by some
groups to be unacceptably high, especially in case of right-
sided pneumonectomy.
University Hospital Leuven, Belgium.
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